Grifols (GRFS) Net Income towards Common Stockholders Growth (3y) (2013 - 2020)
Grifols (GRFS) Net Income towards Common Stockholders Growth (3y) (2013 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.47% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 39.28% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -60.22% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 11.31% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 19.87% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -129.59% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -28.09% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -34.02% |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 10.02% |
| Dec 31, 2019 | 70.15% |
| Mar 31, 2019 | -20.06% |
| Dec 31, 2018 | 77.66% |
| Jun 30, 2018 | 21.02% |
| Mar 31, 2018 | 22.08% |
| Dec 31, 2017 | 14.50% |
| Jun 30, 2017 | -6.13% |
| Mar 31, 2017 | 14.35% |
| Dec 31, 2016 | -31.61% |
| Sep 30, 2016 | 12.31% |
| Jun 30, 2016 | 19.16% |
| Mar 31, 2016 | 46.96% |
| Dec 31, 2015 | -24.53% |
| Sep 30, 2015 | 24.97% |
| Jun 30, 2015 | 20.14% |
| Mar 31, 2015 | 17.91% |
| Dec 31, 2014 | 311.82% |
| Sep 30, 2014 | 134.90% |
| Jun 30, 2014 | 156.70% |